The NACSTOP trial: A multi-center, cluster-controlled trial of early cessation of acetylcysteine in acetaminophen overdose
Hepatology Aug 23, 2018
Wong A, et al. - Given that historically, acetylcysteine has been delivered at a fixed dose and duration of 300 mg/kg over 20 hours to nearly every patient deemed to be at any risk for hepatotoxicity following acetaminophen overdose, researchers examined a 12-hour treatment regimen for selected low-risk patients in this multicenter, open-label, cluster-controlled trial at six metropolitan Emergency Departments. The findings from the present study suggested that discontinuing acetylcysteine based on laboratory testing after 12 hours of treatment was feasible and likely safe in selected patients at very low risk of liver injury from acetaminophen overdose.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries